Expanded Access Study for Renal Transplant Patients With Envarsus XR ™

Inclusion Criteria

• •Eligible patients will fulfill all of the following criteria:
• •1. Patient age ≥18years old
• •2. Willing to give written informed consent and is able to speak, write and understand English
• •3. Patient understands potential risks or benefits with treatment of Envarsus XR
• •4. Patients who have received a primary or secondary kidney transplant
• •5. Patient who have received prior treatment with Envarsus XR (LCP-Tacro) and who are not currently participating in an Envarsus/LCP-Tacro study OR
• •6. The treating Investigator has identified the patient as having a medical necessity for switching from their current tacrolimus treatment to Envarsus XR: Investigator is aware the medical necessity for switching is not related to the inability to purchase available tacrolimus.